Buprenorphine Hydrochloride

We offer biocatalysts and enzymes for the development of substances used in pharmaceuticals, agrochemicals and other fine chemicals from initial screening to commercial scale supply. Our range of biocatalysts complement the chiral capabilities of our chemo-catalyst technology offering. Using our biocatalysis capabilities we can identify and develop enzymes for your processes and API development.

 Johnson Matthey provides a portfolio of advanced heterogeneous catalysts, homogeneous catalysts and chemocatalysts and biocatalysts for the pharmaceutical market. Our expert technical teams will deliver the solutions you need for more cost effective, efficient and sustainable chemistry.

Ultra-pure synthetic cannabidiol at commercial scale

Johnson matthey pharma services offers a wide range of products which includes sodium oxybate. Features: it is used in cns depressant (narcolepsy). Contact us for more information.

In Development - Please contact your Account Manager

In Development - Please contact your Account Manager

In Development - Please contact your Account Manager

In Development - Please contact your Account Manager

In Development - Please contact your Account Manager

In Development - Please contact your Account Manager

In Development - Please contact your Account Manager

Our Controlled Substance and API Portfolio is supported by a global network of GMP facilities: West Deptford, NJ; Devens, MA; North Andover, MA; Edinburgh, UK and Annan, UK.

Johnson Matthey (JM), a global leader in science that enables a cleaner and healthier world, has entered into a five-year supply agreement with Sarepta Therapeutics, Inc. to continue supplying regulatory starting materials to support Sarepta’s phosphorodiamidate morpholino oligomer (PMO) and peptide phosphorodiamidate morpholino oligomer (PPMO) programmes used for the treatment of Duchenne Muscular Dystrophy.

JM provides complex chemistry solutions to the pharma market to create a healthier world. We have vast industry experience, access to specialist technologies and capabilities, and a 200-year heritage.

Johnson Matthey (LSE: JMAT), a global leader in science that enables a cleaner and healthier world, announced a strategic manufacturing partnership for the large-scale production of the drug-linker used in Immunomedics’ lead antibody-drug conjugate. 

Johnson Matthey provides an extensive range of APIs and we have specific expertise in platinum-based actives and prostaglandins. Our products cover a wide range of therapeutics classes, such as: anti-cancer, anti-rheumatic, addiction, psychiatric disorders and ophthalmic indications. Our Controlled Substance and API portfolio is supported by a global network of GMP facilities: West Deptford, NJ; Devens, MA; North Andover, MA; Edinburgh, UK and Annan, UK.

Our expertise in solid state pharmaceutical studies helps to enhance your drug discovery and development by enabling better products and a faster route to market.

Johnson Matthey provides a portfolio of advanced heterogeneous catalysts, homogeneous chemocatalysts and biocatalysts. Our expert technical teams will deliver the solutions you need for more cost effective, efficient and sustainable chemistry.

Our vision is for a world that's cleaner and healthier, today and for future generations.

Johnson Matthey has leading capabilities in developing optimal polymorphs, salt forms, crystal morphology and controlled particles through our PHARMORPHIX®️ solid form sciences. We offer one of the broadest and most reliable services to ensure effective identification, development and manufacture of your drug candidates and commercial products.

Johnson Matthey provides a portfolio of advanced heterogeneous catalysts, homogeneous chemocatalysts and biocatalysts for the pharmaceutical market.

Our Controlled Substance and API portfolio is supported by a global network of GMP facilities: West Deptford, NJ; Devens, MA; North Andover, MA; Edinburgh, UK and Annan, UK.

In the manufacture of active pharmaceutical ingredients (APIs), crystallisation is a key unit operation. The importance of designing the solid state and particle form of a given API is well-appreciated in the industry as it can impact the downstream processability of the isolated material and can be used to maximise the efficacy of the final drug. Crystallisation provides the first-choice opportunity to achieve this designed particle, however, historically time and cost pressures have inhibited developing the understanding required for robust and reliable processes at an early stage. Consequently, issues such as oiling out, solvent and impurity entrapment, multimodal particle size distributions and previously unseen polymorph transitions have been all too common to first be seen upon process scale-up, often requiring significant quantities of additional time and investment to circumvent.